Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 667.99 Million USD | -48.89% |
| 2022 | 1.3 Billion USD | -12.93% |
| 2021 | 1.5 Billion CAD | -5.18% |
| 2020 | 1.58 Billion CAD | 152.94% |
| 2019 | 625.81 Million CAD | -33.84% |
| 2018 | 945.97 Million CAD | 11132.19% |
| 2017 | 8.42 Million CAD | -18.47% |
| 2016 | 10.33 Million CAD | 156.84% |
| 2015 | 4.02 Million CAD | 114.51% |
| 2014 | 1.87 Million CAD | 4539.14% |
| 2013 | 40.41 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 455.61 Million USD | -8.73% |
| 2023 Q4 | 504.31 Million USD | -27.26% |
| 2023 Q3 | 693.27 Million USD | -9.4% |
| 2023 Q2 | 765.16 Million USD | -32.58% |
| 2023 Q1 | 1.13 Billion USD | -13.16% |
| 2023 FY | 667.99 Million USD | -48.89% |
| 2022 Q1 | 1.45 Billion CAD | -2.88% |
| 2022 FY | 1.3 Billion USD | -12.93% |
| 2022 Q4 | 1.3 Billion USD | 8.4% |
| 2022 Q3 | 1.2 Billion CAD | -10.97% |
| 2022 Q2 | 1.35 Billion CAD | -7.11% |
| 2021 Q3 | 1.65 Billion CAD | 8.3% |
| 2021 Q2 | 1.52 Billion CAD | -9.71% |
| 2021 Q4 | 1.5 Billion CAD | -9.22% |
| 2021 Q1 | 1.69 Billion CAD | 6.81% |
| 2021 FY | 1.5 Billion CAD | -5.18% |
| 2020 Q3 | 769.63 Million CAD | 44.21% |
| 2020 Q1 | 635.72 Million CAD | 1.58% |
| 2020 Q2 | 533.69 Million CAD | -16.05% |
| 2020 FY | 1.58 Billion CAD | 152.94% |
| 2020 Q4 | 1.58 Billion CAD | 105.68% |
| 2019 Q4 | 625.81 Million CAD | 12.2% |
| 2019 Q3 | 557.75 Million CAD | -7.73% |
| 2019 Q1 | 805.79 Million CAD | -14.82% |
| 2019 FY | 625.81 Million CAD | -33.84% |
| 2019 Q2 | 604.48 Million CAD | -24.98% |
| 2018 FY | 945.97 Million CAD | 11132.19% |
| 2018 Q4 | 945.97 Million CAD | 19.52% |
| 2018 Q2 | 910.16 Million CAD | 46.73% |
| 2018 Q3 | 791.49 Million CAD | -13.04% |
| 2018 Q1 | 620.28 Million CAD | 7265.09% |
| 2017 Q2 | 9.57 Million CAD | -3.41% |
| 2017 Q4 | 8.42 Million CAD | -4.22% |
| 2017 FY | 8.42 Million CAD | -18.47% |
| 2017 Q1 | 9.91 Million CAD | -4.03% |
| 2017 Q3 | 8.79 Million CAD | -8.18% |
| 2016 Q2 | 7.44 Million CAD | 80.28% |
| 2016 FY | 10.33 Million CAD | 156.84% |
| 2016 Q4 | 10.33 Million CAD | 44.07% |
| 2016 Q3 | 7.17 Million CAD | -3.65% |
| 2016 Q1 | 4.12 Million CAD | 2.64% |
| 2015 Q4 | 4.02 Million CAD | 1.21% |
| 2015 Q2 | 5.89 Million CAD | 211.96% |
| 2015 FY | 4.02 Million CAD | 114.51% |
| 2015 Q1 | 1.89 Million CAD | -1.3% |
| 2015 Q3 | 3.97 Million CAD | -32.63% |
| 2014 Q1 | 1.87 Million CAD | 4618.41% |
| 2014 Q3 | 1.87 Million CAD | 0.0% |
| 2014 Q2 | - CAD | -100.0% |
| 2014 Q4 | 1.91 Million CAD | 2.19% |
| 2014 FY | 1.87 Million CAD | 4539.14% |
| 2013 Q3 | 40.41 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | 40.41 Thousand CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | 39.73 Thousand CAD | -1.68% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | -1032.816% |
| Harrow Health, Inc. | 190.5 Million USD | -250.652% |
| Dynavax Technologies Corporation | 256.91 Million USD | -160.009% |
| Biofrontera Inc. | 5.39 Million USD | -12272.643% |
| Cronos Group Inc. | 2.53 Million USD | -26199.815% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -109768.257% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 6.644% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1739.052% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -56847.62% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -3524.818% |
| Radius Health, Inc. | 365.31 Million USD | -82.857% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -12084.302% |
| DURECT Corporation | 20.74 Million USD | -3119.893% |
| ProPhase Labs, Inc. | 21.38 Million USD | -3024.411% |
| Safety Shot Inc | 1.54 Million USD | -43025.256% |
| Phibro Animal Health Corporation | 525.45 Million USD | -27.127% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -25131.741% |
| Alvotech | 1.07 Billion USD | 37.888% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1532.77% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1508.59% |
| Rockwell Medical, Inc. | 13.43 Million USD | -4870.6% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -101465.139% |
| Procaps Group S.A. | 285.93 Million USD | -133.619% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -3843.789% |
| SCYNEXIS, Inc. | 15.08 Million USD | -4329.702% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -4315.355% |
| Viatris Inc. | 18.12 Billion USD | 96.314% |
| OptiNose, Inc. | 131.74 Million USD | -407.024% |
| SIGA Technologies, Inc. | 1.46 Million USD | -45528.066% |
| Tilray Brands, Inc. | 387.31 Million USD | -72.468% |
| PetIQ, Inc. | 468.3 Million USD | -42.643% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -101465.139% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -55.929% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | -891.111% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 0.932% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -61314.24% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -459.693% |
| Journey Medical Corporation | 17.73 Million USD | -3667.62% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -7970.944% |
| Alpha Teknova, Inc. | 30.45 Million USD | -2093.181% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -31907.619% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -412.426% |
| PainReform Ltd. | 86 Thousand USD | -776643.023% |
| Cosmos Health Inc. | 12.42 Million USD | -5276.703% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1787.856% |
| TherapeuticsMD, Inc. | 8 Million USD | -8244.772% |
| Embecta Corp. | 1.63 Billion USD | 59.231% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -1116824.44% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | -13.984% |
| Incannex Healthcare Limited | 373 Thousand USD | -178988.204% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -64558.726% |
| Shineco, Inc. | 29.65 Million USD | -2152.458% |
| Procaps Group, S.A. | 285.93 Million USD | -133.619% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -111.843% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -575.962% |
| Lantheus Holdings, Inc. | 616.94 Million USD | -8.275% |
| Alvotech | 1.07 Billion USD | 37.888% |
| Hempacco Co., Inc. | 13.72 Million USD | -4767.199% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -969.38% |
| Bright Green Corporation | 1.85 Million USD | -35973.287% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -23.487% |
| Kamada Ltd. | 8.74 Million USD | -7535.158% |
| Indivior PLC | 281.6 Million USD | -137.214% |
| Evoke Pharma, Inc. | 5 Million USD | -13259.98% |
| Flora Growth Corp. | 3.67 Million USD | -18091.694% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -64558.726% |
| Evolus, Inc. | 126.54 Million USD | -427.87% |
| HUTCHMED (China) Limited | 86.13 Million USD | -675.562% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | -7.113% |
| Akanda Corp. | 3.99 Million USD | -16605.024% |